NASDAQ · CGEM
Cullinan Therapeutics, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for CGEM: Nov 5, 2026
Cullinan Therapeutics, Inc. Common Stock is estimated to report earnings on 11/05/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 6 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.79. The reported EPS for the same quarter last year was $-0.77.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.79 | $-0.71 | $-0.86 | 6 |
| Dec 2026 | $-0.71 | $-0.36 | $-0.89 | 6 |
| Mar 2027 | $-0.41 | $-0.35 | $-0.44 | 3 |
| Jun 2027 | $-0.71 | $-0.49 | $-0.92 | 3 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Zacks · MarketBeat · RTTNews- Zacks · Oct 29, 8:55 AM EDTDoes Cullinan Therapeutics (CGEM) Have the Potential to Rally 129.63% as Wall Street Analysts Expect?The mean of analysts' price targets for Cullinan Therapeutics (CGEM) points to a 129.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
- MarketBeat · Oct 28, 9:45 AM EDT3 Growth Stocks Under $20 With Hard Catalyst Dates AheadSmall caps led the market into spring and have been handing it back ever since. The Russell 2000 has cooled, defense and drone names sit well off their highs, and the riskier corners of biotech and critical minerals have been marked down right alongside them. That creates a spec
- RTTNews · Oct 8, 9:43 AM EDTCullinan Moves CLN-049 Into Phase 2 Development For Relapsed/Refractory AML(RTTNews) – Cullinan Therapeutics (CGEM) announced Thursday that the first patient has been dosed in its pivotal Phase 2 study of CLN-049 in patients with relapsed or refractory acute myeloid leukemia (AML).
- RTTNews · Oct 1, 11:50 PM EDTCullinan's Zipalertinib Combination Heads To FDA After Positive Phase 3 Lung Cancer Trial(RTTNews) – Cullinan Therapeutics (CGEM) announced that it has initiated submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration for zipalertinib in combination with platinum-based chemotherapy as a first-line treatment for patients with EGFR exon 20 i
- MarketBeat · Sep 28, 7:02 AM EDTCullinan Therapeutics Eyes December Data Catalyst for CLN-978 and CLN-049Cullinan Therapeutics (NASDAQ:CGEM) outlined upcoming clinical milestones across its immunology and oncology pipeline, including a planned December update for its CD19-directed T-cell engager CLN-978 and data presentations for other programs in November and the fourth quarter. P
- RTTNews · Sep 24, 7:36 AM EDTCullinan Therapeutics Outlines Q4 Milestones For T Cell Engager Pipeline(RTTNews) – Cullinan Therapeutics, Inc. (CGEM) outlined fourth-quarter 2026 milestones across its immunology and oncology pipeline, including clinical updates for velinotamig, CLN-978 and CLN-049.
- RTTNews · Sep 13, 10:19 PM EDTCullinan's Zipalertinib Plus Chemotherapy Extends PFS By 6 Months In EGFR Ex20+ Lung Cancer(RTTNews) – Cullinan Therapeutics, Inc (CGEM), Taiho Oncology and Taiho Pharmaceutical reported additional results from the Phase 3 REZILIENT3 trial of Zipalertinib plus platinum-based chemotherapy in first-line treatment of patients with advanced EGFR exon 20 insertion-mutated n
- RTTNews · Sep 11, 3:24 AM EDTCullinan Therapeutics To Present Phase 3 REZILIENT3 Data At IASLC 2026 On Sunday(RTTNews) – Cullinan Therapeutics Inc. (CGEM), a clinical-stage biopharmaceutical company focused on advancing first- or best-in-class, disease-modifying T cell engagers for autoimmune diseases and cancer, announced that results from the planned interim analysis of its Phase 3 RE
- RTTNews · Aug 27, 5:22 AM EDTBiotech Stocks At 52-Week Highs – CRDL, NEO, SPTX, RAPP, CGEM(RTTNews) – The following biotech stocks reached a 52-week high on August 26, 2026, as clinical trials continued enrolment and companies reached various regulatory milestones.
- RTTNews · Aug 15, 2:59 AM EDTWeekly Buzz: LNTH, CBLL Win FDA Nod; AURA Cuts Jobs; TDY Buys VREX; CGEM, DFTX Meet Trial Goals(RTTNews) – This week's global biopharma sector roundup captured a mix of regulatory wins, restructuring activities, deals that expanded company pipelines, and clinical trial readouts.
- RTTNews · Aug 13, 7:25 AM EDTShow Me The Money: Did You Miss CGEM's Rally? Here's What Comes Next(RTTNews) – It has been a banner year so far for Cullinan Therapeutics Inc. (CGEM), with multiple positive clinical readouts across its pipeline fueling share price momentum.
- RTTNews · Aug 13, 1:03 AM EDTCullinan, Taiho's Zipalertinib – Chemotherapy Combo Meets Key Goal In Phase 3 NSCLC Trial; Stock Up(RTTNews) – Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Cullinan Therapeutics, Inc. (CGEM) announced that the Phase 3 REZILIENT3 trial, evaluating the combination of zipalertinib and platinum-based chemotherapy in the first-line treatment of locally advanced or meta
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Cullinan Therapeutics, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.